Outcomes at index therapy by index treatment
| Treatment group . | N . | % . | 2-year EFS (95% CI) . | 5-year OS (95% CI) . |
|---|---|---|---|---|
| All treatments | 220 | 100 | 24% (19-30) | 71% (64-78) |
| Anti-CD20 monotherapy | 18 | 8 | 37% (20-69) | 73% (53-100) |
| Bendamustine ± CD20 | 32 | 15 | 30% (17-51) | 74% (59-93) |
| CHOP ± CD20 | 46 | 21 | 17% (9-33) | 67% (54-84) |
| Intensive salvage therapy | 52 | 24 | 20% (11-35) | 63% (51-78) |
| Lenalidomide based | 19 | 9 | 35% (19-66) | 84% (66-100) |
| Nonsystemic | 7 | 3 | 50% (22-100) | 100% (100-100) |
| Other chemotherapy | 15 | 7 | 14% (4-52) | 72% (52-100) |
| Radioimmunotherapy | 12 | 5 | 33% (15-74) | 51% (28-94) |
| Targeted therapy | 19 | 9 | 11% (3-39) | 84% (66-100) |
| Treatment group . | N . | % . | 2-year EFS (95% CI) . | 5-year OS (95% CI) . |
|---|---|---|---|---|
| All treatments | 220 | 100 | 24% (19-30) | 71% (64-78) |
| Anti-CD20 monotherapy | 18 | 8 | 37% (20-69) | 73% (53-100) |
| Bendamustine ± CD20 | 32 | 15 | 30% (17-51) | 74% (59-93) |
| CHOP ± CD20 | 46 | 21 | 17% (9-33) | 67% (54-84) |
| Intensive salvage therapy | 52 | 24 | 20% (11-35) | 63% (51-78) |
| Lenalidomide based | 19 | 9 | 35% (19-66) | 84% (66-100) |
| Nonsystemic | 7 | 3 | 50% (22-100) | 100% (100-100) |
| Other chemotherapy | 15 | 7 | 14% (4-52) | 72% (52-100) |
| Radioimmunotherapy | 12 | 5 | 33% (15-74) | 51% (28-94) |
| Targeted therapy | 19 | 9 | 11% (3-39) | 84% (66-100) |